5-Methyl-3-(1-methylethoxy)-2-thiophenecarboxylic acid | 113589-52-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Methyl-3-(1-methylethoxy)-2-thiophenecarboxylic acid
• 英文别名: 5-methyl-3-propan-2-yloxythiophene-2-carboxylic acid
• CAS: 113589-52-9
• 化学式: C₉H₁₂O₃S
• 分子量: 200.26
• InChiKey: ZKEQXQWEEQHCHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-Methyl-3-(1-methylethoxy)-2-thiophenecarboxylic acid 、 5-氨基四氮唑 生成 5-methyl-3-propan-2-yloxy-N-(2H-tetrazol-5-yl)thiophene-2-carboxamide
  参考文献：
  名称：

  CETENKO, WIACZESLAW A.;CONNOR, DAVID T.;MULLICAN, MICHAEL D.;SORENSON, RO+

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl 3-(1-methylethoxy)-5-methyl-2-thiophenecarboxylate 、 sodium hydroxide 以61%的产率得到
  参考文献：
  名称：

  MULLICAN, MICHAEL D.;SORENSON, RODERICK J.;CONNOR, DAVID T.;THUESON, DAVI+, J. MED. CHEM., 34,(1991) N, C. 2186-2194

  摘要：

  DOI：

文献信息

• N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：EP3928836A1

  公开（公告）日：2021-12-29

  The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，涉及它们的制备、它们的药学上可接受的盐，以及它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为前列腺素 2 受体 EP2 和/或 EP4 的调节剂的用途。
• N-substituted indole derivatives as PGE2 receptor modulators
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：US11241431B2

  公开（公告）日：2022-02-08

  The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的衍生物 其中 (R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，涉及它们的制备、它们的药学上可接受的盐，以及它们作为药物的用途、含有一种或多种式 (I) 化合物的药物组合物，特别是它们作为前列腺素 2 受体 EP2 和/或 EP4 的调节剂的用途。
• Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US11325899B2

  公开（公告）日：2022-05-10

  The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.

  本发明涉及式 (I) 的苯并呋喃和苯并噻吩衍生物 其中(R1)n、R2、R3、R4a、R4b、R5a、R5b 和 Ar1 如说明书所述，以及它们通过调节免疫反应（包括重新激活肿瘤中的免疫系统）治疗癌症的用途。本发明进一步涉及式(II)的新型苯并呋喃和苯并噻吩衍生物及其作为药物的用途、它们的制备、它们的药学上可接受的盐及其作为药物的用途、含有一种或多种式(I)化合物的药物组合物，特别是它们作为前列腺素2受体EP2和/或EP4的调节剂的用途。
• CETENKO, WIACZESLAW A.;CONNOR, DAVID T.;MULLICAN, MICHAEL D.;SORENSON, RO+
  作者：CETENKO, WIACZESLAW A.、CONNOR, DAVID T.、MULLICAN, MICHAEL D.、SORENSON, RO+

  DOI：——

  日期：——
• MULLICAN, MICHAEL D.;SORENSON, RODERICK J.;CONNOR, DAVID T.;THUESON, DAVI+, J. MED. CHEM., 34,(1991) N, C. 2186-2194
  作者：MULLICAN, MICHAEL D.、SORENSON, RODERICK J.、CONNOR, DAVID T.、THUESON, DAVI+

  DOI：——

  日期：——